Pcsk9 antagonists

Details Pcsk9 antagonists Pcsk9 antagonists

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61P 3/06 (2006.01) C07K 16/40 (2006.01)

Patent

CA 2736349

The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholes-terolemia.

La présente invention concerne des anticorps antagonisants, des parties de liaison avec lantigène de ces anticorps, et des aptamères qui se lient à la proprotéine convertase subtilisine/kexine de type 9 (PCSK9). L'invention concerne également des anticorps dirigés contre des peptides, où les anticorps se lient à PCSK9. Linvention concerne en outre un procédé permettant dobtenir de tels anticorps et un acide nucléique codant pour les anticorps. Linvention concerne également des méthodes thérapeutiques permettant dutiliser ces anticorps et parties de liaison avec lantigène de ces anticorps pour réduire les niveaux de cholestérol LDL et/ou pour le traitement et/ou la prévention de maladies cardiovasculaires, y compris le traitement de lhypercholestérolémie.

Affiliated with

Also associated with

Rating

Pcsk9 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pcsk9 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pcsk9 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1738586